Flavopiridol Strongly Sensitizes Canine Lymphoma Cells to TRAIL-induced Apoptosis
Aleksandra Pawlak1, Diego DE Miguel2,3, Justyna Kutkowska4
1Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wrocław University of Environmental and Life Sciences, Wroclaw, Poland aleksandra.pawlak@upwr.edu.pl.
Background/Aim:
Targeting the extrinsic apoptotic pathway is an interesting option for anticancer therapy. A protein which such ability is Apo2 ligand, also known as TNF-related apoptosis-inducing ligand (TRAIL). The aim of this study was to examine the possibility of sensitizing resistant CLBL-1 canine lymphoma cells to TRAIL-induced apoptosis by using flavopiridol (FVP) a cyclin-dependent kinase inhibitor (CDKs).
Materials And Methods:
The CLBL-1 (canine B-cell lymphoma cell line) was used in the study. The effect of FVP and TRAIL treatment on apoptosis induction was assessed by flow cytometry and western blot.
Results:
Although canine lymphoma cells were resistant to TRAIL-induced apoptosis, combination of this death ligand with FVP was able to overcome TRAIL resistance of CLBL-1 lymphoma cells.
Conclusion:
Our results demonstrated that although canine lymphoma cells were resistant to TRAIL-induced apoptosis, combination of this death ligand with FVP was able to overcome TRAIL resistance of CLBL-1 lymphoma cell line. Although further investigation is required to deepen the knowledge of TRAIL as an antitumor agent in canine cancers, our results open the door to future use of TRAIL-based treatment strategies in veterinary oncology.
Insights
Flavopiridol (FVP) overcomes TRAIL resistance in canine lymphoma cells. This combination therapy shows promise for veterinary oncology, targeting the extrinsic apoptotic pathway in canine cancers.
Area of Science:
- Oncology
- Molecular Biology
- Veterinary Medicine
Background:
- Targeting the extrinsic apoptotic pathway is a potential anticancer strategy.
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis.
- Canine lymphoma cells often exhibit resistance to TRAIL-induced apoptosis.
Purpose of the Study:
- To investigate if flavopiridol (FVP), a cyclin-dependent kinase inhibitor (CDK), can sensitize resistant CLBL-1 canine lymphoma cells to TRAIL.
- To evaluate the potential of combining FVP with TRAIL for overcoming TRAIL resistance in canine lymphoma.
Main Methods:
- Utilized the CLBL-1 canine B-cell lymphoma cell line.
- Assessed apoptosis induction using flow cytometry and western blot analysis.
- Examined the effects of FVP and TRAIL treatment, both individually and in combination.
Main Results:
- Canine lymphoma cells demonstrated resistance to TRAIL-induced apoptosis when treated with TRAIL alone.
- The combination of FVP and TRAIL successfully overcame TRAIL resistance in CLBL-1 cells.
- FVP treatment sensitized resistant canine lymphoma cells to TRAIL-mediated apoptosis.
Conclusions:
- The combination of FVP and TRAIL is effective in overcoming TRAIL resistance in canine lymphoma cells.
- This combination strategy holds potential for future TRAIL-based treatment in veterinary oncology.
- Further research is needed to fully elucidate TRAIL's role in canine cancer therapy.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
10:13Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
